January 2021
The UK rollout plan for the Oxford/AstraZeneca vaccine has been changed, but Pfizer/BioNTech say their vaccine was not designed to be used in two shots 12 weeks apart:
Three more coronavirus vaccines are expected early this year, from Novavax, AstraZeneca and Johnson & Johnson:
A novel computational drug screening strategy developed in China has determined that pralatrexate outperforms remdesivir in inhibiting the Covid-19 virus:
The pharmaceutical industry sifts through the details of the EU trade deal:
What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies:
According to the report “Contract Research Organization (CRO) Market” the global contract research organisation market size is expected to surge at 11.48% CAGR through to 2023:
The Europe contract research organization (CRO) market is expected to grow with a CAGR of 7.7% from 2018-2025:
Moderna has announced the Phase 3 study of its COVID-19 vaccine candidate, mRNA-1273, has demonstrated efficacy of 94.5%:
Sunderland-based CRO Onyx Scientific has announced a multi-million pound investment in its facility which will be used for non-GMP & GMP Phase I – III and commercial API manufacturing:
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a guidance document for clinical trial sponsors and research organisations dealing with the submission of Suspected Unexpected Serious Adverse Drug Reactions and Development Safety Update Reports following the end of the Brexit transition period (requires free trial registration):
Archive
- July 2022
- June 2022
- April 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
